Decreasing R&D/sales percentage with severe polarization among companies
The listed pharmaceutical companies’ percentage of R&D expenses to sales is decreasing while the polarization among companies in the category is getting severe.
Yakup Shinmoon(www.yakup.com) analyzed 2018 business reports that 65 listed pharmaceutical companies made, and the analysis result show...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
